Transactional and Corporate HEALTHCARE AND PHARMACEUTICALS

Our business lawyers are renowned for their work on mergers and acquisitions, IPOs, strategic alliances and corporate governance matters. Drawing on the resources of our intellectual property, tax, labor and employment, employee benefits, regulatory, real estate, bankruptcy and financial restructuring, litigation and antitrust practices, we provide a one-stop solution to our healthcare and life sciences clients. Serving a diverse range of clients, from public and private companies to individual entrepreneurs, our corporate lawyers have:

  • Served as issuer counsel or underwriters' counsel in more than 400 public offerings and Rule 144A placements raising nearly $150 billion since 2006 
  • Advised on more than 1,000 M&A deals with a total value in excess of $400 billion since 2006 
  • Handled hundreds of strategic alliances, joint ventures, outsourcing and licensing transactions each year, including several strategic alliances that have received industry recognition for their importance

Experience

With our extensive experience, we can meet all of a clients' needs cost-effectively, while also offering the complete resources of a major international law firm. With approximately 1,000 lawyers and 12 offices in the United States, Europe and Asia, WilmerHale is well qualified to represent clients on transactions in the healthcare arena both in the United States and internationally. Our Transactional Department has received a number of accolades over the years in many different areas, solidifying our position as a market leader. For example, Chambers USA has named our Corporate Practice among the best each year from 2012 to 2017, with sources saying WilmerHale is a "highly esteemed firm" and "superb" with "outstanding quality at all levels." Finally, Chambers USA has recognized WilmerHale's life sciences practice in the top tier both globally and in the United States since 2008.

  • Mergers & Acquisitions: We have particular strength in advising public and private companies in all aspects of mergers and acquisitions. In 2016, we advised clients throughout the United States and Europe on more than 75 M&A transactions with an aggregate value in excess of $50 billion. Our experience ranges from public-public mergers and related SEC, disclosure and fiduciary duty issues to the unique issues presented by sales of private equity and venture-backed private companies.
  • Corporate Finance: WilmerHale has wide-ranging experience in public offerings of equity and debt securities in the US and international markets. We have served as issuer counsel or underwriters' counsel in more than 400 public offerings and Rule 144A placements for leading companies in the healthcare, life sciences, technology, financial services and communications industries, raising more than $150 billion since 2006. Our regular representation of the world's leading investment banks as underwriters and financial services companies as lenders affords us a perspective that is useful in counseling our issuer and borrower clients. We have a wide array of capital markets experience, including traditional underwritten offerings, registered direct offerings, 144A placements and other private placement transactions involving equity, trust preferred securities, convertible notes, unsecured notes and secured notes. In addition, we have significant commercial finance expertise in secured and unsecured credit facilities, commercial paper programs, trade debt, real estate financing, project financing, acquisition financing and specialty financing transactions.
  • Public Company Counseling: WilmerHale advises public companies in connection with securities, disclosure and corporate governance matters, including SEC reporting, Regulation FD, the Sarbanes-Oxley Act and stock market listing. We also help our public company clients plan for and defend against unsolicited acquisition offers, respond to dissident stockholders and implement anti-takeover strategies. In advising clients on these matters, we draw on the experience accumulated from our ongoing representation of approximately 100 public companies in the US and Europe. Our team includes seasoned transactional lawyers, as well as former senior staff members from the SEC with a wealth of regulatory insight.
  • Technology, Transactions and Licensing: WilmerHale's technology transactions and licensing lawyers leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate technology-related agreements. We apply the depth and breadth of our experience to generate value for our clients. As a result, LMG Life Sciences ranked the firm in its 2013-2016 editions in areas including patent prosecution, corporate, licensing and collaboration, venture capital and M&A. The firm was also named a "Life Cycle Firm" from 2012-2016, meaning the firm is regarded as one of the best full-service law firms serving the life sciences industry. Each year, we handle hundreds of strategic alliances, joint ventures, outsourcing and licensing transactions. The complexity of these deals often demands deep experience and close collaboration among our corporate, licensing, intellectual property and tax lawyers. Our lawyers in the United States, Europe and Asia work together seamlessly to find the right solution for our clients' business. We regularly advise clients across a broad spectrum of industries, including:
    • Healthcare and medical devices
    • Biotechnology and pharmaceuticals
    • Information technology and electronics
    • Internet and e-commerce
    • Nanotechnology

Publications & News

View

January 30, 2018

WilmerHale Represents Ocular Therapeutix™ in Public Offering of Common Stock

Ocular Therapeutix™, Inc. announced the closing of its underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $5.00 per share.

January 26, 2018

WilmerHale Represents Karyopharm in Agreement with Biogen to Acquire KPT-350

Karyopharm Therapeutics Inc. announced its entry into an agreement for Biogen to acquire Karyopharm's investigational oral SINE compound KPT-350 and other assets for the treatment of certain neurological and neurodegenerative conditions.

January 26, 2018

WilmerHale Represents Spark Therapeutics in Licensing and Supply Agreement With Novartis

Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the United States.

January 3, 2018

WilmerHale Represents Viamet Pharmaceuticals in Acquisition by NovaQuest Capital Management

Viamet Pharmaceuticals (NC), Inc. today announced that it has entered into an agreement with NovaQuest Capital Management, L.L.C. for the acquisition of Viamet Pharmaceuticals, including the company's product candidate, VT-1161.

December 22, 2017

WilmerHale Advises Centurion in Acquisition by Medline

On December 7, 2017, Medline completed its acquisition of Centurion Medical Products, a Michigan-based medical supplies manufacturer. The company will continue to operate as a subsidiary of Medline.

December 15, 2017

WilmerHale Reps Decibel Therapeutics in Strategic Collaboration With Regeneron

On November 29, 2017, Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc. announced a collaboration to discover and develop new potential therapeutics to protect, repair and restore hearing.

December 11, 2017

WilmerHale Represents Editas Medicine in $50M Offering of Common Stock

Editas Medicine, Inc., a leading genome editing company, announced the pricing of an underwritten offering of 1,970,000 shares of its common stock.

December 5, 2017

Astellas Acquires Mitobridge Under Existing Collaboration

Astellas Pharma Inc. and Mitobridge, Inc. announced that Astellas has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement.

November 17, 2017

WilmerHale Reps Achillion Pharmaceuticals in Pricing of Secondary Offering of Common Stock

Achillion Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson Innovation-JJDC, Inc., which shares constitute all of JJDC's equity position in Achillion, at a public offering price of $2.75 per share.

November 14, 2017

WilmerHale Reps Apellis Pharmaceuticals in Initial Public Offering

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced the closing of its initial public offering.